Sandra Levy
ARTICLES BY THIS AUTHOR
- 3/31/2020
Camber debuts glycerin liquid, syrup line
Camber has expanded its offerings to include Glycerin liquid and a line of three syrups. - 3/31/2020
CVS Pharmacy expands benefits, safety measures for employees
CVS Pharmacy announced new employee benefits and safety measures to keep employees and customers safe during the COVID-19 pandemic. - 3/31/2020
Higi supports COVID-19 prevention efforts with education and free online digital symptom checker
Higi is launching a partnership with Babylon Health, to offer its users a free, self-service, online COVID-19 digital symptom checker, as well as clinical guidance on when to seek testing and potential treatment. - 3/30/2020
NCPA survey: Pharmacists back access to experimental COVID-19 treatment
Ninety percent of local pharmacists are reporting a shortage of hydroxychloroquine, according to an NCPA survey. - 3/29/2020
Zydus gets FDA's tentative nod for generic Rytary
Zydus Cadila's generic Rytary is indicated to treat Parkinson's disease. - 3/29/2020
CDMA donates 45,000 pairs of gloves to 2 Detroit hospitals
Beaumont and Henry Ford hospitals in Detroit have received 22,500 pairs of gloves each from CDMA. - 3/29/2020
Kinney Drugs increases wages, installs protective shields for workers
All 97 Kinney Drugs locations have acrylic shields installed in the pharmacy drop-off and pick-up areas, as well as at the front registers, to protect customers and employees. - 3/29/2020
Abbott launches rapid point-of-care COVID-19 test
Abbott's molecular point-of-care test for COVID-19 delivers positive results in as little as five minues, and negative results in 13 minutes. - 3/29/2020
CVS Health, foundations pledge $1M in employee, community relief
CVS Health and its foundations are providing financial investments to help communities and employees facing COVID-19 pandemic-related hardships. - 3/29/2020
J&J, U.S. government plan 1B COVID-19 vaccine doses
J&J and the U.S. government are committing more than $1 billion for research and development of a novel coronavirus vaccine, which could be ready for emergency use by early 2021.
